Moomoo AIのまとめ
Robert Davidow has filed an amendment with the Securities and Exchange Commission, indicating a change in his ownership stake in Avenue Therapeutics, Inc. According to the Schedule 13G/A filed on May 2, 2024, Davidow now owns less than 5% of the company's common stock, specifically 17,206 shares, which represents 2.9% of the class. This filing is an update to the previous Schedule 13G filings made in November and December 2023. The shares are held in various forms, including individual ownership, joint accounts with his wife, trusts for his children, and accounts over which he has shared dispositive authority. The reporting also reflects the impact of a 75-for-1 reverse stock split that took effect on April 26, 2024. Davidow has disclaimed beneficial ownership of the shares except to the extent of his pecuniary interest and has certified that the shares were not acquired for the purpose of changing or influencing the control of the issuer.
Robert Davidow has filed an amendment with the Securities and Exchange Commission, indicating a change in his ownership stake in Avenue Therapeutics, Inc. According to the Schedule 13G/A filed on May 2, 2024, Davidow now owns less than 5% of the company's common stock, specifically 17,206 shares, which represents 2.9% of the class. This filing is an update to the previous Schedule 13G filings made in November and December 2023. The shares are held in various forms, including individual ownership, joint accounts with his wife, trusts for his children, and accounts over which he has shared dispositive authority. The reporting also reflects the impact of a 75-for-1 reverse stock split that took effect on April 26, 2024. Davidow has disclaimed beneficial ownership of the shares except to the extent of his pecuniary interest and has certified that the shares were not acquired for the purpose of changing or influencing the control of the issuer.
Robert DavidowはSecurities and Exchange Commissionに修正書類を提出し、Avenue Therapeutics, Inc.での所有権の変更を示しています。2024年5月2日に提出されたSchedule 13G/Aによると、Davidowは現在、同社の普通株式の5％未満、具体的には17,206株を所有し、これはそのクラスの2.9％を占めています。この申請は、2023年11月および12月に行われた以前のSchedule 13Gの更新です。これらの株式は、個人所有、妻との共同口座、子供のための信託、および共有の処分権を持っている口座など、様々な形態で所有...すべて展開
Robert DavidowはSecurities and Exchange Commissionに修正書類を提出し、Avenue Therapeutics, Inc.での所有権の変更を示しています。2024年5月2日に提出されたSchedule 13G/Aによると、Davidowは現在、同社の普通株式の5％未満、具体的には17,206株を所有し、これはそのクラスの2.9％を占めています。この申請は、2023年11月および12月に行われた以前のSchedule 13Gの更新です。これらの株式は、個人所有、妻との共同口座、子供のための信託、および共有の処分権を持っている口座など、様々な形態で所有されています。この報告書には、2024年4月26日に実施された75対1の逆株式分割の影響も反映されています。Davidowは、株式の有益な所有権を放棄しており、自己の利益に応じたものであり、発行体の支配権を変更または影響を与える目的で取得されたものではないことを証明しています。
役に立った
役に立たない
この開示の添付ファイルは以下です：